132 related articles for article (PubMed ID: 16457270)
1. [Prognostic significance of CA19-9 levels in patients with pancreatic cancer].
Shiozawa S; Tsuchiya A; Kim DH; Ogawa K
Nihon Rinsho; 2006 Jan; 64 Suppl 1():297-300. PubMed ID: 16457270
[No Abstract] [Full Text] [Related]
2. The past, present, and future of biomarkers: a need for molecular beacons for the clinical management of pancreatic cancer.
Brody JR; Witkiewicz AK; Yeo CJ
Adv Surg; 2011; 45():301-21. PubMed ID: 21954696
[No Abstract] [Full Text] [Related]
3. Serum tumor markers for pancreatic cancer: the dawn of new era?
Okusaka T; Yamada T; Maekawa M
JOP; 2006 Jul; 7(4):332-6. PubMed ID: 16832130
[No Abstract] [Full Text] [Related]
4. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.
Ko AH; Hwang J; Venook AP; Abbruzzese JL; Bergsland EK; Tempero MA
Br J Cancer; 2005 Jul; 93(2):195-9. PubMed ID: 15999098
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
[TBL] [Abstract][Full Text] [Related]
6. CA 19-9 response as an early indicator of the effectiveness of gemcitabine in patients with advanced pancreatic cancer.
Nakai Y; Kawabe T; Isayama H; Sasaki T; Yagioka H; Yashima Y; Kogure H; Arizumi T; Togawa O; Ito Y; Matsubara S; Hirano K; Sasahira N; Tsujino T; Tada M; Omata M
Oncology; 2008; 75(1-2):120-6. PubMed ID: 18784438
[TBL] [Abstract][Full Text] [Related]
7. CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone.
Wasan HS; Springett GM; Chodkiewicz C; Wong R; Maurel J; Barone C; Rosbrook B; Ricart AD; Kim S; Spano JP
Br J Cancer; 2009 Oct; 101(7):1162-7. PubMed ID: 19724276
[TBL] [Abstract][Full Text] [Related]
8. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer.
Halm U; Schumann T; Schiefke I; Witzigmann H; Mössner J; Keim V
Br J Cancer; 2000 Mar; 82(5):1013-6. PubMed ID: 10737382
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.
Maréchal R; Demols A; Gay F; De Maertelaere V; Arvanitaki M; Hendlisz A; Van Laethem JL
Oncology; 2007; 73(1-2):41-51. PubMed ID: 18334830
[TBL] [Abstract][Full Text] [Related]
10. Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: pretreatment levels or kinetics during chemotherapy?
Boeck S; Schulz C; Stieber P; Holdenrieder S; Weckbach S; Heinemann V
Onkologie; 2007 Feb; 30(1-2):39-42. PubMed ID: 17264524
[TBL] [Abstract][Full Text] [Related]
11. Combining the Glasgow Prognostic Score and Serum Carbohydrate Antigen 19-9 Level Improves the Ability to Predict Early Recurrence in Resected Pancreatic Cancer Patients Receiving Adjuvant Gemcitabine.
Numata K; Morinaga S; Katayama Y; Sawazaki S; Numata M; Godai T; Higuchi A; Shiozawa M; Rino Y; Masuda M; Akaike M
Anticancer Res; 2016 May; 36(5):2467-74. PubMed ID: 27127159
[TBL] [Abstract][Full Text] [Related]
12. [Changes in tumor marker levels as a predictor of gemcitabine effect on patients with unresectable or recurrent pancreatic cancer].
Tendo M; Nakata B; Nishino H; Inoue M; Kosaka K; Amano R; Yamada N; Hirakawa K
Gan To Kagaku Ryoho; 2005 Jun; 32(6):795-8. PubMed ID: 15984518
[TBL] [Abstract][Full Text] [Related]
13. Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival.
Takahashi H; Ohigashi H; Ishikawa O; Eguchi H; Gotoh K; Yamada T; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K; Yano M
Ann Surg; 2010 Mar; 251(3):461-9. PubMed ID: 20134315
[TBL] [Abstract][Full Text] [Related]
14. CA19-9: a pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin.
Heinemann V; Schermuly MM; Stieber P; Schulz L; Jüngst D; Wilkowski R; Schalhorn A
Anticancer Res; 1999; 19(4A):2433-5. PubMed ID: 10470171
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine.
Saad ED; Machado MC; Wajsbrot D; Abramoff R; Hoff PM; Tabacof J; Katz A; Simon SD; Gansl RC
Int J Gastrointest Cancer; 2002; 32(1):35-41. PubMed ID: 12630768
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer.
Ikeda M; Okada S; Tokuuye K; Ueno H; Okusaka T
Br J Cancer; 2002 May; 86(10):1551-4. PubMed ID: 12085203
[TBL] [Abstract][Full Text] [Related]
17. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial.
Hess V; Glimelius B; Grawe P; Dietrich D; Bodoky G; Ruhstaller T; Bajetta E; Saletti P; Figer A; Scheithauer W; Herrmann R
Lancet Oncol; 2008 Feb; 9(2):132-8. PubMed ID: 18249033
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemotherapy.
Tsutsumi K; Kawamoto H; Hirao K; Sakakihara I; Yamamoto N; Noma Y; Fujii M; Kato H; Ogawa T; Ishida E; Kuwaki K; Nouso K; Okada H; Yamamoto K
Pancreatology; 2012; 12(5):409-16. PubMed ID: 23127528
[TBL] [Abstract][Full Text] [Related]
19. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.
Small W; Berlin J; Freedman GM; Lawrence T; Talamonti MS; Mulcahy MF; Chakravarthy AB; Konski AA; Zalupski MM; Philip PA; Kinsella TJ; Merchant NB; Hoffman JP; Benson AB; Nicol S; Xu RM; Gill JF; McGinn CJ
J Clin Oncol; 2008 Feb; 26(6):942-7. PubMed ID: 18281668
[TBL] [Abstract][Full Text] [Related]
20. CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma.
Ali CW; Kaye TF; Adamson DJ; Tait IS; Polignano FM; Highley MS
J Gastrointest Cancer; 2007; 38(2-4):108-14. PubMed ID: 19089662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]